

For Immediate Release

**Alembic Pharmaceuticals Ltd.  
Consolidated Results for quarter ended 30.09.2011**

**Revenues up 24% at Rs 398 crores against Rs. 321 crores in PY  
PBT up 47% at Rs 45 crores against Rs. 30.6 crores in PY**

**Editors Synopsis**

- **Net sales up 24% at Rs 398 crores against Rs. 321 crores in corresponding quarter last year**
- **Domestic formulations up 10% at Rs. 227 crores against Rs. 207 crores in corresponding quarter last year**
- **International Generics up by 79% to Rs. 71 crores vis-à-vis Rs. 40 crores last year**
- **Total API sales up 47% at Rs. 82 crores against Rs. 56 crores in corresponding quarter last year**
- **Profit before tax up by 47% at Rs. 45.04 crores against Rs. 30.60 crores in corresponding quarter in last year**

Vadodara, 19<sup>th</sup> October, 2011

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 24% increase in revenues to Rs 398.05 crores for the quarter ended 30th September 2011, compared to Rs 321.17 crores in the corresponding quarter last year.

The Company posted an impressive 47% growth in profit before tax at Rs. 45.04 crores for the quarter ended September 2011 against Rs 30.60 crores posted in corresponding quarter last fiscal.

EBIDTA margins for quarter ended September 11 up at 15.19% from 13.21% for corresponding quarter last year.

#### International Business

International Generics to the regulated markets grew by 79% to Rs. 71.38 crores from Rs. 39.79 Crores over the corresponding quarter last year.

Formulations sales to ROW markets amounted to Rs. 12.04 crores against Rs. 14.95 crores in corresponding quarter last year.

Export of API products grew by 50% to Rs. 60.44 crores from Rs. 40.41 crores over corresponding quarter last year.

Cumulative DMF filings at 56. Cumulative ANDA filings at 41. Cumulative ANDA approvals now stands at 15.

#### Domestic Formulation Business

The domestic formulation business posted sales of Rs. 226.92 crores against Rs. 206.83 crores registering 10% growth over the corresponding quarter last year.

Alembic has maintained a market share of 1.86%. The positive impact of the restructuring undertaken in the recent past is evident from the encouraging numbers.

Alembic has four brands in the list of top 300 brands of the industry i.e. 'Azithral' , 'Roxid', 'Althrocin', and 'Wikoryl'.

## Domestic API Business

Domestic API sales recorded a growth of 40% at Rs. 22.01 crores against Rs. 15.69 crores of PY.

### Summary of total revenue (consolidated) for the quarter:

(Rs. in Lacs)

Particulars	Consolidated		
	Q2 FY12	Q2 FY11	% Change
<b>Formulation</b>			
Domestic	22692	20683	10%
International Branded	1204	1495	(-)19%
International Generics	7138	3979	79%
<b>API</b>			
Domestic	2201	1569	40%
International	6044	4041	50%
Export incentives	526	350	50%
<b>Total</b>	<b>39805</b>	<b>32117</b>	<b>24%</b>

### The Profit break-up for the quarter:

(Rs. in Lacs)

Particulars	Consolidated		
	Q2 FY12	Q2 FY11	% Change
Operating Income	6047	4243	43%
Profit Before Tax	4504	3060	47%
Net Profit after Tax	3804	2521	51%

The previous year's figures are approx. and unaudited numbers of relevant businesses which were then part of Alembic Limited. These are given just for comparison purpose.

## About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of anti-infective drugs in India.

Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

**For more information:**

**Alembic Pharmaceuticals Limited**

**Mitanshu Shah**

**0265 – 3007630**

**[mitanshu.shah@alembic.co.in](mailto:mitanshu.shah@alembic.co.in)**